Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models - Wikidata - awgldk - TriplyDB

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

http://www.wikidata.org/entity/Q37208563

about

An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer Targeting Cell Survival Proteins for Cancer Cell Death Biomarkers in triple negative breast cancer: A review HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers The molecular chaperone Hsp90α is required for meiotic progression of spermatocytes beyond pachytene in the mouse Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2 The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding Selective targeting of the stress chaperome as a therapeutic strategy Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer Assay strategies for the discovery and validation of therapeutics targeting Brugia pahangi Hsp90 Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins A purine analog synergizes with chloroquine (CQ) by targeting Plasmodium falciparum Hsp90 (PfHsp90)Dynamic impacts of the inhibition of the molecular chaperone Hsp90 on the T-cell proteome have implications for anti-cancer therapy A novel pulse-chase SILAC strategy measures changes in protein decay and synthesis rates induced by perturbation of proteostasis with an Hsp90 inhibitor Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia.Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.Targeting highly expressed extracellular HSP90 in breast cancer stem cells inhibits tumor growth in vitro and in vivo.Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling.Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer Protein chaperones: a composition of matter review (2008 - 2013).Getting folded: chaperone proteins in muscle development, maintenance and disease.Synergetic cytotoxic activity toward breast cancer cells enhanced by the combination of Antp-TPR hybrid peptide targeting Hsp90 and Hsp70-targeted peptide.Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics.HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans Triple-negative breast cancer.The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.Activity of the heat shock protein 90 inhibitor ganetespib in melanoma Standard of care and promising new agents for triple negative metastatic breast cancer HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization.Design, synthesis, and evaluation of small molecule Hsp90 probes.

P2860

Q21134999-90DF48CF-5F60-4BB1-93FA-55E3676FBCFF Q24616764-EEE61C9E-001E-41BA-9499-DCFC2AC0B90A Q26752846-6A4798B2-0353-40EC-AAAF-EBE67ED0C33D Q26765447-A98CF81E-079D-45DB-95CC-A381D0460AC5 Q26775094-D0DCBCEA-FFE7-46AA-B9F2-D5CA133DFC48 Q26778548-4E24C8D7-B899-4F2F-9388-60002DE200EB Q26864290-FC5001BC-E4A8-4275-AC9F-F304D2FD38D4 Q27022514-33D16148-A53C-41B3-BF2C-4CE09733B55E Q27438098-EA46E1BF-112B-4FA3-9D48-C5DBC78FA9B0 Q27679845-049EE3B3-7929-49BD-B0F4-C7FCB01A45E0 Q28115175-5AAD3611-59DC-4C03-B0D2-E45203ACB81B Q28248791-7C56674A-C9B9-4DBD-9FDD-C1786A2F2D7E Q28264693-13DA25CC-2005-4056-8A9E-E4BCF5761FAC Q28294781-26F33164-7789-4271-94F8-D9269DCBDEFD Q28387216-EAF91780-7E01-4E88-A9C6-B7EC5ED18CA5 Q28474428-AB27B78E-08BE-4860-B3C8-0C4983D63223 Q28485399-FDEAF3E5-DC61-4AD8-892D-1B2FCD0794E4 Q28533944-8961AB7D-A18C-476B-9693-0C6C9CA577B6 Q28535465-CFAF0B1A-C072-4579-9522-33E933ADE038 Q28535467-7EA91C37-2A3F-4EFE-9666-AD3243DCEF47 Q30313260-CDBAFE3E-FA3F-4DD1-88B9-997CB6EF51A0 Q30313615-8CB96418-8E95-49D2-91C4-1572DF7F5F24 Q30805174-CD2D20C5-8CD2-4656-8411-B812493E6ED0 Q33527397-C488217E-B29F-4B82-9D75-6F0CEF712442 Q33588432-E430B6E6-94C0-42E8-A604-42A4388ED0E2 Q33703311-0CD9DD88-6F75-402D-B8DF-2B15387F11A1 Q33710107-6E69423E-5C8A-4247-9FBA-3F81E5CE2142 Q33786774-3275DF9B-27B6-41A2-9D0B-06EF7077E120 Q33917578-708B7C2E-F15D-4A87-B9FD-034FFE209E35 Q34013266-9B9173E2-2B54-426B-B29D-6A938DE7A147 Q34055646-C59DCE67-0F52-44D7-998F-B7F810B983F5 Q34129993-7F090AD1-B850-4D27-887A-A9BF140F8F29 Q34140962-BFB70BB8-3372-4105-A34B-24C71E37318D Q34162151-7908C81D-A74B-433A-84D1-3D9E0D4E3F78 Q34274939-2E848D4E-ABF3-4418-9FFF-870949FCDDEF Q34282588-8DAB4FA2-5D06-4255-A15E-1535EC595CF9 Q34589866-C1B62A3B-A173-4BF9-B5AF-0529BEFD6215 Q34774884-20F940F9-EA95-4F62-8473-3E7B1FE670DD Q35044046-BC5D3340-4B35-4E81-9B54-46E91316C622 Q35128528-D117CCE1-CED1-4D98-BE29-4FA930ACA961

P2860

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

http://www.wikidata.org/entity/Q37208563

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Hsp90 inhibitor PU-H71, a mult ...... -negative breast cancer models

@en

Hsp90 inhibitor PU-H71, a mult ...... negative breast cancer models.

@nl

type

label

Hsp90 inhibitor PU-H71, a mult ...... -negative breast cancer models

@en

Hsp90 inhibitor PU-H71, a mult ...... negative breast cancer models.

@nl

prefLabel

Hsp90 inhibitor PU-H71, a mult ...... -negative breast cancer models

@en

Hsp90 inhibitor PU-H71, a mult ...... negative breast cancer models.

@nl

P1433

Q37208563-925866A7-DAA8-4B03-87AB-3F95456ED161

P1476

Q37208563-4DC67B90-A931-4181-94B0-7C957442BB41

P2093

Q37208563-0287D5B2-0887-48D3-B3B7-4BC9D346B946

Q37208563-225A7271-385A-44C7-9515-1372A4DB85EA

Q37208563-2BEFB2AF-AC50-4A40-8972-952A5ED59475

Q37208563-364E604A-9F21-4499-9C4C-85ADCAE22534

Q37208563-4BCF6F97-88FA-478A-A09C-D9D3408E37C4

Q37208563-5BBA5442-A029-47E5-8D3C-FD30A9F30D23

Q37208563-75A94C37-F1E6-4EA7-B322-EA058AA28A31

Q37208563-7B43CE69-F959-46DB-8914-611ED1FC4718

Q37208563-88885C6C-9478-4C04-A1E2-D40B8A35F576

Q37208563-AA4426EA-3FA0-4D28-9F9A-83320B3609AF

P2860

Q37208563-023A5D5F-D67F-42F1-B1FF-9ADB64DCB484

Q37208563-02BDCE6D-0C3B-4C86-A95B-45B1F70BBFDA

Q37208563-0BEDA3B8-10FA-4653-8969-351A0AEDFAFD

Q37208563-1A3ACF54-F897-499B-B5B5-836743E35015

Q37208563-2398668A-AC20-485E-9271-FF1213195AF0

Q37208563-3D1B0D45-C3CB-4384-852C-F6B44DCAB6E7

Q37208563-471487D8-70A7-4C67-BDBE-B334032B3584

Q37208563-4797DC18-0ADF-497F-9B66-C77CAF5DD675

Q37208563-4E69E05D-1D62-4F51-9A72-3F5D8A03B673

Q37208563-5E1698F0-B320-4196-B134-7968BDC88BB5

P304

Q37208563-F4C52E16-2E8A-4038-830F-8A9313539C04

P31

Q37208563-08B25709-6C2C-4D2B-B4EF-CB33CCFDB666

P356

Q37208563-0BBA6964-0322-492A-BD9F-5F5D42B9EF0C

P407

Q37208563-F352B2B6-BD28-46E1-9F3E-8B4B9630BC81

P433

Q37208563-2E37D049-7368-444D-9A38-FA1A09004A8F

P478

Q37208563-6FCE0353-6DF3-4273-B372-C85E7E6E03C4

P50

Q37208563-04C4C7E7-486C-494F-9F64-67CF5BBFB5CC

Q37208563-0CFC18D2-BD1D-4524-A0DC-52F1FC467B87

Q37208563-7935E825-E811-43F3-87F3-32160BF3ECE0

Q37208563-C89DC7EE-03DA-4792-B803-5A2C132BE0C0

Q37208563-DBB152C1-1A7F-4829-B620-205E31EC46C1

P577

Q37208563-8CC344D6-129C-4B37-B88A-BB8C18D9077E

P5875

Q37208563-AF65B2D8-EF52-406E-BE0A-0DF8B9F0AF4F

P698

Q37208563-CE44E9CF-1C34-4534-82CF-0EE29A3C84BD

P932

Q37208563-58C7ACE4-FD93-4811-8751-EEA878AE5C2D

P356

PNAS.0903392106

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Hsp90 inhibitor PU-H71, a mult ...... -negative breast cancer models

@en

P2093

Alexander Gozman

http://www.w3.org/2001/XMLSchema#string

Ana I Robles

http://www.w3.org/2001/XMLSchema#string

Anna Rodina

http://www.w3.org/2001/XMLSchema#string

Ari Melnick

http://www.w3.org/2001/XMLSchema#string

James H Ahn

http://www.w3.org/2001/XMLSchema#string

Julie White

http://www.w3.org/2001/XMLSchema#string

Kamalika Moulick

http://www.w3.org/2001/XMLSchema#string

Lyuba Varticovski

http://www.w3.org/2001/XMLSchema#string

Nian Wu

http://www.w3.org/2001/XMLSchema#string

Steven S Gross

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation and function of IKK and IKK-related kinases

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress

Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1

Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation.

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Advancements of antisense oligonucleotides in treatment of breast cancer.

SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.

Hsp90: an emerging target for breast cancer therapy.

Hsp70 molecular chaperones: emerging roles in human disease and identification of small molecule modulators.

P304

8368-8373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0903392106

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Gabriela Chiosis

Eloisi Caldas-Lopes

Leandro Cerchietti

Elisa de Stanchina

Cristina C Clement

P577

2009-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24403043

http://www.w3.org/2001/XMLSchema#string

P698

19416831

http://www.w3.org/2001/XMLSchema#string

P932

2688867

http://www.w3.org/2001/XMLSchema#string